PET/CT imaging of Mycobacterium tuberculosis infection

Clinical and Translational Imaging

Volumn 4, Issue 2, 2016, Pages 131-144

  Ankrah, Alfred O ^a,b   van der Werf, Tjip S ^a   de Vries, Erik F J ^a   Dierckx, Rudi A J O ^a   Sathekge, Mike M ^b   Glaudemans, Andor W J M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

18F fluoroethylcholine; 68Ga citrate; 3 Deoxy 3 18F fluoro l thymidine; PET CT; Tuberculosis

Indexed keywords

3' FLUOROTHYMIDINE F 18; CAPREOMYCIN; CARBON 11; CHOLINE C 11; CULTURE FILTRATE PROTEIN 10; EARLY SECRETORY ANTIGENIC TARGET 6; FLUORODEOXYGLUCOSE F 18; FLUOROETHYLCHOLINE F 18; GALLIUM CITRATE GA 68; ISONIAZID; KANAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RADIOPHARMACEUTICAL AGENT; RIFAMPICIN; SODIUM FLUORIDE F 18; TRACER; UNCLASSIFIED DRUG;

BACTERIAL TRANSMISSION; CD4 LYMPHOCYTE COUNT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; DISEASE COURSE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATORY INFILTRATE; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOPHYSIOLOGY; POSTPRIMARY TUBERCULOSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT RESPONSE; TUBERCULIN TEST; TUBERCULOSIS;

EID: 84967261244     PISSN: 22815872     EISSN: 22817565     Source Type: Journal    
DOI: 10.1007/s40336-016-0164-0     Document Type: Review

References (121)

1. Young DB, Gideon HP, Wilkinson RJ (2009) Eliminating latent tuberculosis. Trends Microbiol 17(5):183–188
2. World Health Organization (2015) Global tuberculosis report 2015 (20th edition): www.who.int/tb/publications/global_report. Assessed 23 Nov 2015
3. Zumla A, Raviglione M, Hafner R, von Reyn CF (2013) Tuberculosis. N Engl J Med 368(8):745–755. doi:10.1056/NEJMra1200894
4. Zumla A, George A, Sharma V, Herbett RH, Baroness Masham of Ilton, Oxley A, Oliver M (2015) The WHO 2014 global tuberculosis report—further to go. Lancet Global Health 3(1):e10–e12. doi:10.1016/S2214-109X(14)70361-4
5. Hershkovitz I, Donoghue HD, Minnikin DE, Besra GS, Lee OY, Gernaey AM et al (2008) Detection and molecular characterization of 9,000-year old Mycobacterium tuberculosis from a Neolithic settlement in the Eastern Mediterranean. PLoS ONE 3(10):e3426. doi:10.1371/journal.pone.0003426
6. Aziz MA, Wright A, Laszlo A, De Muynck A, Portaels F, Van Deun A et al (2006) Epidermiology of antituberculous drug resistance (The Global Project on Anti-tuberculous drug resistance): an updated analysis. Lancet 368(9553):2142–2154
7. Zignol M, van Gemert W, Falzon D, Sismondi’s C, Glaziou P, Floyd K, Raviglione M (2012) Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007–2010. Bull World Health Organ 90(2):111D–119D. doi:10.2471/BLT.11.092585
8. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN et al (2012) Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 9(8):E1001300
9. Resch SC, Salomon JA, Murray M, Weinstein MC (2006) Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med 3(7):e241
10. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC (1999) Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282(7):677–686
11. Corbett EL, Watt CJ, Walker N, Mahar D, Williams BG, Raviglione MC, Dye C (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163(9):1009–1021
12. Andrews JR, Noubary F, Walensky RP, Cerda R, Losina E, Horshburgh CR (2012) Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin Infect Dis 54(6):784–791. doi:10.1093/cid/cir951
13. Hanrahan CF, Shah M (2014) Economic challenges associated with tuberculosis diagnostic development. Expert Rev Pharmacoecon Outcomes Res 14(4):499–510. doi:10.1586/14737167.2014.914438
14. Johnson DH, Via LE, Kim P, Laddy D, Lau CY, Weinstein EA, Jain S (2014) Nuclear imaging: a powerful novel approach for tuberculosis. Nuc Med Biol 41(10):777–784. doi:10.1016/j.nucmedbio.2014.08.005
15. van Altena R, Duggirala S, Gröschel MI, van der Werf TS (2011) Immunology in tuberculosis: challenges in monitoring of disease activity and identifying correlates of protection. Curr Pharm Des 17(27):2853–2862
16. Prabowo SA, Gröschel MI, Schmidt ED, Skrahina A, Mihaescu T, Hastürk S et al (2013) Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines. Med Microbiol Immunol 202(2):95–104. doi:10.1007/s00430-012-0278-6
17. Gautam US, Sikri K, Vashit A, Singh V, Tyagi JS (2014) Essentiality of DevR/DosR interaction with SigA for the dormancy survival program in Mycobacterium tuberculosis. J Bacteriol 196(4):790–799. doi:10.1128/JB.01270-13
18. Dutta NK, Karakousis PC (2014) Latent tuberculosis infection: myths, models and molecular mechanisms. Microbiol Mol Biol Rev 78(3):342–371. doi:10.1128/MMBR.00010-14
19. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV et al (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393(6685):537–544
20. North RJ, Izzo AA (1993) Virulent strains of Mycobacteria have faster in vivo doubling times and are better equipped to resist growth-inhibiting functions of macrophages in the presence and absence of specific immunity. J Exp Med 177(6):1723–1733
21. Jakubowiak WM, Bogorodskaya EM, Borisov SE, Danilova ID, Kourbatova EV (2007) Risk factors associated with default among new pulmonary TB patients and social support in six Russian regions. Int J Tuberc Lung Dis 11(1):46–53
22. Faustini A, Hall AJ, Perucci CA (2006) Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax 61(2):158–163
23. Hett EC, Rubin EJ (2008) Bacterial growth and cell division: a mycobacterial perspective. Microbiol Mol Biol Rev 72(1):126–156. doi:10.1128/MMBR.00028-07
24. Faller M, Niederweis M, Schulz GE (2004) The structure of a mycobacterial outer-membrane channel. Science 303(5661):1189–1192
25. Houben EN, Korotkov KV, Bitter W (2014) Take five—Type VII secretion systems of Mycobacteria. Biochim Biophys Acta 1843(8):1707–1716. doi:10.1016/j.bbamcr.2013.11.003
26. Rajni Rao N, Meena LS (2011) Biosynthesis and virulent behavior of lipids produced by Mycobacterium tuberculosis: LAM and cord factor: an overview. Biotechnol Res Int 2011:27469. doi:10.4061/2011/274693.3
27. Brennan PJ (2003) Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis (Edinb) 83(1–3):91–97
28. Trivedi A, Singh N, Bhat SA, Gupta P, Kumar A (2012) Redox biology of tuberculosis pathogenesis. Adv Microb Physiol 60:234–263. doi:10.1016/B978-0-12-398264-3.00004-8
29. Mehra S, Foreman TW, Didier PJ, Ahsan MH, Hudock TA, Kissee R et al (2015) The DosR Regulon modulates adaptive immunity and is essential for Mycobacterium tuberculosis persistence. Am J Respir Crit Care Med 191(10):1185–1196. doi:10.1164/rccm.201408-1502OC
30. Simeone R, Sayes F, Song O, Gröschel MI, Brodin P, Brosch R, Majlessi L (2015) Cytosolic access of Mycobacterium tuberculosis: critical impact of phagosomal acidification control and demonstration of occurrence in vivo. PLoS Pathog 11(2):e1004650. doi:10.1371/journal.ppat.1004650
31. Smith J, Manoranjan J, Pan M, Bohsali A, Xu J, Liu J et al (2008) Evidence for pore formation in host cell membranes by ESX-1-secreted ESAT-6 and its role in Mycobacterium marinum escape from the vacuole. Infect Immun 76(12):5478–5487. doi:10.1128/IAI.00614-08
32. Abdallah AM, Gey van Pittius NC, Champion PA, Cox J, Luirink J, Vandenbroucke-Grauls CM, Appelmelk BJ, Bitter W (2007) Type VII secretion–mycobacteria show the way. Nat Rev Microbiol 5(11):883–891
33. Loudon RG, Spohn SK (1969) Cough frequency and infectivity in patients with pulmonary tuberculosis. Am Rev Respir Dis 99(1):109–111
34. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E et al (2011) Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 365(23):2155–2166. doi:10.1056/NEJMoa1104875
35. Kumar A, Farhana A, Guidry L, Saini V, Hondalus M, Steyn AJ (2011) Redox homeostasis in mycobacteria: the key to tuberculosis control? Exp Rev Mol Med 13:e39. doi:10.1017/S1462399411002079
36. Lawn SD, Zumla AL (2011) Tuberculosis. Lancet 378(9785):57–72. doi:10.1016/S0140-6736(10)62173-3
37. Narasimhan P, Wood J, MacIntyre CR, Mathai D (2013) Risk factors for tuberculosis. Pulm Med 2013:828939. doi:10.1155/2013/828939
38. Lönnroth K, Williams BG, Stadlin S, Jaramillo E, Dye C (2008) Alcohol use as a risk factor for tuberculosis—a systemic review. BMC Public Health 8:289. doi:10.1186/1471-2458-8-289
39. Caws M, Thwaites G, Dunstan S, Hawn TR, Lan NT, Thuong NT et al (2008) The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis. PLoS Pathog 4(3):e1000034. doi:10.1371/journal.ppat.1000034
40. von Reyn CF (2011) Optimal treatment of Codisease due to HIV and tuberculosis. J Infect Dis 204(6):817–819. doi:10.1093/infdis/jir418
41. von Reyn CF, Kimambo S, Mtei L, Arbeit RD, Maro I, Bakari M et al (2011) Disseminated tuberculosis in human immunodeficiency virus infection: ineffective immunity, polyclonal disease and high mortality. Int J Tuberc Lung Dis 15(8):1087–1092. doi:10.5588/ijtld.10.0517
42. Mudenda V, Lucas S, Shibemba A, O’Grady J, Bates M, Kapata N et al (2012) Tuberculosis and tuberculosis/HIV/AIDS-associated mortality in Africa: the urgent need to expand and invest in routine research autopsies. J Infect Dis 205(Suppl 2):s340–s346. doi:10.1093/infdis/jir859
43. Drobniewski FA, Caws M, Gibson A, Young D (2003) Modern laboratory diagnosis of tuberculosis. Lancet Infect Dis 3(3):141–147
44. Ichyiama S, Shimokata K, Takeuchi J (1993) Comparative study of a biphasic culture system (Roche MB Check system) with a conventional egg media for recovery of mycobacteria. Aichi Mycobacteriosis research Group. Tuber Lung Dis 74(5):338–341
45. Zar HJ, Cornell TG, Nicol M (2010) Diagnosis of pulmonary tuberculosis in children: new advances. Expert Rev Anti Infect Ther 8(3):277–288. doi:10.1586/eri.10.9
46. Jain SK, Ordonez A, Klinkar A, Gupte N, Thakar M, Mave V et al (2013) Pediatric tuberculosis in young children in India: a prospective study. Biomed Res Int 2013:783698. doi:10.1155/2013/783698
47. Mitchison DA (2005) The diagnosis and therapy of tuberculosis during the past 100 years. Am J Respir Crit Care Med 171(7):699–706
48. van Dyck P, Vanhoenacker FM, Van de Brande P, De Schepper AM (2003) Imaging of pulmonary tuberculosis. Eur Radiol 13:1771–1785
49. Khan MA, Kovnat DM, Bachus B, Whitcomb ME, Broody JS, Snider GL (1977) Clinical and roentgenographic spectrum of pulmonary tuberculosis in the adult. Am J Med 62(1):31–38
50. Perlman DC, el-Sadr WM, Nelson ET, Matts JP, Telzek EE, Salomon N et al (1997) Variation of chest radiograph patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. The Terry Beirn Community Programs for Clinical Research on Aids (CPCRA). The AIDS Clinical Trial Group (ACTG). Clin Infect Dis 25(2):242–246
51. Roy A, Eisenhut M, Harris RJ, Rodrigues LC, Sridhar S, Habermann S, Snell L et al (2014) Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ 349:g4643. doi:10.1136/bmj.g4643
52. Pai M, Zwerling A, Menzies D (2008) Systemic review: T cell based assays for the diagnosis of latent TB infection: an update. Ann Intern Med 149(3):177–184
53. Metcalfe JZ, Everett CK, Steingart KR, Cattamanchi A, Huang L, Hopewell PC, Pai M (2011) Interferon- γ release assays for active pulmonary tuberculosis diagnosis in low- and middle-income countries: systematic review and meta-analysis. J Infect Dis 204(Suppl. 4):S1120–S1129. doi:10.1093/infdis/jir410
54. Lawn SD, Kerkhoff AD, Vogt M, Wood R (2012) Diagnostic accuracy of a low cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis 12(3):201–209. doi:10.1016/S1473-3099(11)70251-1
55. Chang K, Lu W, Wang J, Zhang K, Jia S, Li F et al (2012) Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. J Infect 64(6):580–588. doi:10.1016/j.jinf.2012.02.012
56. Sohn H, Aero AD, Menzies D, Behr M, Schwartzman K, Alvarez GG et al (2014) Xpert MTB/RIF testing in low TB incidence, high resource setting: limitation s in accuracy and clinical impact. Clin Infect Dis 58(7):970–976. doi:10.1093/cid/ciu022
57. Kayigire XA, Friedrich SO, Venter A, Dawson R, Gillespie SH, Boeree MJ et al (2013) Direct comparison of Xpert MTB/RIF assay with liquid and solid mycobacterial culture for quantification of early bacterial activity. J Clin Microbiol 51(6):1894–1898. doi:10.1128/JCM.03290-12
58. Gumbo T, Pasipanodya JG, Wash P, Burger A, McIlleron H (2014) Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy. Antimicrob Agents Chemother 58(10):6111–6115. doi:10.1128/AAC.03549-14
59. Gumbo T, Angulo-Barturen I, Ferrer-Bazaga S (2015) Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia. J Infect Dis 211(Suppl 3):S96–S106. doi:10.1093/infdis/jiu610
60. Skoura E, Zumla A, Bomanji J (2015) Imaging in tuberculosis. Int J Infect Dis 32:87–93. doi:10.1016/j.ijid.2014.12.007
61. Sathekge M, Maes A, Van De Wiele C (2013) FDG-PET imaging in HIV infection and tuberculosis. Semin Nucl Med 43(5):349–366. doi:10.1053/j.semnuclmed.2013.04.008
62. 18F-FDG PET and PET/CT Curr Opin Pulm Med 20(3):287–93. doi:10.1097/MCP.0000000000000043
63. Ichiya Y, Kuwabara Y, Sasaki M, Yoshida T, Akashi Y, Murayama S et al (1996) FDG-PET in infectious lesions: the detection and assessment of lesion activity. Ann Nucl Med 10(2):185–191
64. Goo JM, Im JG, Do KH, Yeo JS, Seo JB, Kim HY, Chung JK (2000) Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology 216(1):117–121
65. Sathekge M, Maes A, Kgomo M, Stoltz A, Pottel H, Van de Wiele C (2010) Impact of FDG PET on the management of TBC treatment. A pilot study. Nuklearmedizin 49(1):35–40. doi:10.3413/nukmed-0270
66. Hara T, Kosaka N, Suzuki T, Kudo K, Niino H (2003) Uptake rates of 18F-fluorodeoxyglucose and 11C-choline in lung cancer and pulmonary tuberculosis: a positron tomography study. Chest 124(3):893–901
67. Mamede M, Higashi T, Kitaichi M, Ishizu K, Ishimori T, Nakamoto Y et al (2005) [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancer cells and inflammatory lesions of the lung. Neoplasia 7(4):369–379
68. Yen RF, Chen KC, Lee JM, Chang YC, Wang J, Cheng MF et al (2008) F-FDG PET for lymph node staging of non-small cell cancer in a tuberculous-endemic country: is dual time point imaging worth the effort? Eur J Nucl Med Mol Imaging 35(7):1305–1315. doi:10.1007/s00259-008-0733-1
69. Tian G, Xiao Y, Chen B, Guan H, Deng QY (2010) Multi-site abdominal tuberculosis mimics malignancy on 18F-FDG PET/CT: report of three cases. World J Gastroenterol 16(33):4237–4242
70. Hadley GP, Naude F (2009) Malignant solid tumor, HIV and tuberculosis in children: an unholy triad. Pediatr Surg Int 25(8):697–701. doi:10.1007/s00383-009-2409-8
71. Lee SH, Min JW, Lee CH, Park CM, Goo JM, Chung DH et al (2011) Impact of parenchymal tuberculosis sequelae on mediastinal lymph node staging in patients with lung cancer. J Korean Med Sci 26(1):67–70. doi:10.3346/jkms.2011.26.1.67
72. Bakheet SM, Powe J (1998) Benign causes of 18-FDG uptake on whole body imaging. Semin Nucl Med 28(4):352–358
73. Chang JM, Lee HJ, Goo JM, Lee HY, Lee JJ, Chung JK, Im JM (2006) False positive and false negative FDG-PET scan in various thoracic disease. Korean J Radiol 7(1):57–69
74. Cloran FJ, BamksKP Song WS, Kim Y, Bradley YC (2010) Limitation of dual time point PET in the assessment of lung nodules with low FDG avidity. Lung Cancer 68(1):66–71. doi:10.1016/j.lungcan.2009.05.013
75. Cheng G, Torigan DA, Zhuang H, Alavi A (2013) When should we recommend use of dual time-point and delayed time point imaging techniques in FDG PET. Eur J Nucl Med Mol Imaging 40(5):779–787. doi:10.1007/s00259-013-2343-9
76. Kim DW, Park SA, Kim CG (2011) Dual-time-point positron emission tomography findings of benign mediastinal fluorine-18-fluorodeoxyglucose uptake in tuberculosis endemic region. Indian J Nucl Med 26(1):3–6. doi:10.4103/0972-3919.84586
77. Kim IJ, Lee JS, Kim SJ, Kim YK, Jeong YJ, Jun S et al (2008) Double-phase F-FDG PET-CT for determination of pulmonary tuberculoma activity. Eur J Nucl Med Mol Imaging 35(4):808–814
78. Heysell SK, Thomas TA, Sirifi CD, Rehm PK, Houpt ER (2013) 18-Fluorodeoxyglucose positron emission tomography for tuberculosis diagnosis and management: a case series. BMC Pulm Med 13:14. doi:10.1186/1471-2466-13-1
79. Barry CE 3rd, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J et al (2009) The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 7(12):845–855. doi:10.1038/nrmicro2236
80. Lin P, Flyn JL (2010) Understanding latent tuberculosis: a moving target. J Immunol 185(1):15–22. doi:10.4049/jimmunol.0903856
81. Demura Y, Tsuchida T, Uesaka D, Umeda Y, Morikawa M, Ameshima S et al (2009) Usefulness of 18F-fluorodeoxyglucose positron emission tomography for diagnosing disease activity and monitoring therapeutic response in patients with pulmonary mycobacteriosis. Eur J Nucl Med Mol Imaging 36(4):632–639
82. Sathekge M, Maes A, Kgomo M, Stoltz A, Van de Wiele C (2011) Use of 18F-FDG PET to predict response to first-line tuberculostatics in HIV-associated tuberculosis. J Nucl Med 52(6):880–885. doi:10.2967/jnumed.110.083709
83. Hofmeyr A, Lau WF, Slavin MA (2007) Mycobacterium tuberculosis infection in patients with cancer, the role of 18-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring disease response. Tuberculosis 87(5):459–463
84. Park IN, Ryu JS, Shim TS (2008) Evaluation of therapeutic response of tuberculoma using F-18 FDG positron emission tomography. Clin Nucl Med 33(1):1–3
85. Chen RY, Dodd LE, Lee M, Paripati P, Hammoud DA, Mountz JM et al (2014) PET/CT imaging correlates with treatment outcome in patients with multidrug resistant tuberculosis. Sci Transl Med 6(256):265ra166. doi:10.1126/scitranslmed.3009501
86. Kim SJ, Kim IJ, Suh KT, Kim YK, Lee JS (2009) Prediction of residual disease of spine infection using F-18 FDG PET/CT. Spine 34(22):2424–2430
87. Kim K, Kim SJ, Kim IJ, Kim BS, Pak K, Kim H (2011) Diffuse increased splenic F-18 fluorodeoxyglucose uptake may be an indirect sign of acute pyogenic cause rather than tuberculous in patients with infectious spondylitis. Nucl Med Commun 32(12):1155–1161. doi:10.1097/BRS.0b013e3181b1fd33
88. Dureja S, Sen IS, Acharya S (2014) Potential role of F18 FDG PET-CT as an imaging biomarker for noninvasive evaluation in uncomplicated skeletal tuberculosis: a prospective clinical observational study. Eur Spine J 23(11):2449–2454. doi:10.1007/s00586-014-3483-8
89. Sathekge M, Maes A, Kgomo M, Pottel H, Stolz A, Van De Wiele C (2010) FDG uptake in lymph nodes in HIV+ and tuberculosis patients: implications for cancer staging. Q J Nucl Med Mol Imaging 54(6):698–703
90. Hahm CR, Park HY, Jeon K, Um SW, Suh GY, Chung MP et al (2010) Solitary pulmonary nodules caused by Mycobacterium tuberculosis and Mycobacterium avium complex. Lung 188(1):25–31. doi:10.1007/s00408-009-9203-1
91. Maturu VN, Agarwal R, Aggarwal AN, Mittal BR, Bal A, Gupta N, Gupta D (2014) Dual-time point whole-body 18F-fluorodeoxyglucose PET/CT imaging in undiagnosed mediastinal lymphadenopathy: a prospective study of 117 patients with sarcoidosis and TB. Chest 146(6):e216–e220. doi:10.1378/chest.14-1827
92. Tian G, Xiao Y, Chen B, Xia J, Guan H, Deng Q (2010) FDG PET/CT for therapeutic response monitoring in multi-site non-respiratory tuberculosis Acta Radiol 51(9):1002–1006. doi:10.3109/02841851.2010.504744
93. Sathekge MM, Maes A, Pottel H, Stoltz A, van de Wiele C (2010) Dual time-point FDG PET-CT for differentiating benign from malignant solitary pulmonary nodules in a TB endemic area. S Afr Med J 100(9):598–601
94. 18F-FDG-PET/CT in the differential diagnosis of solitary pulmonary nodules in areas with high incidence of tuberculosis. Ann Nucl Med 25(10):804–811. doi:10.1007/s12149-011-0530-y
95. 18F-FDG PET-CT scan and its histopathologic correlation. Ann Thoracic Med 6(1):11–16. doi:10.4103/1817-1737.74270
96. Soussan M, Brillet PY, Mekinian A, Khafagy A, Nicolas P, Vessieres A, Brauner M (2012) Patterns in pulmonary tuberculosis on FDG-PET/CT. Eur J Radiol 81(10):2872–2876. doi:10.1016/j.ejrad.2011.09.002
97. Sathekge M, Maes A, D’Asseler Y, Vorster M, Gongxeka H, Van de Wiele C (2012) Tuberculous lymphadenitis: FDG PET and CT findings in responsive and nonresponsive disease. Eur J Nucl Med Mol Imaging 39(7):1184–1190. doi:10.1007/s00259-012-2115-y
98. Martinez V, Castilla-Lievre MA, Guillet-Caruba C, Grenier G, Fior R, Desarnaud S et al (2012) Int J Tuberc Lung Dis 16(9):1180–1185. doi:10.5588/ijtld.12.0010
99. Coleman MT, Chen RY, Lee M, Lin PL, Dodd LE, Maiello P et al (2014) PET/CT imaging reveals a therapeutic response to oxalidiones in macques and humans with tuberculosis Sci Trans Med 6(265):265ra167. doi:10.1126/scitranslmed.3009500
100. Jeong YJ, Paen JC, Nam HY, Lee JS, Lee SM, Yoo CG et al (2014) (18)F-FDG positron emission tomography/computer tomography findings of radiographic lesions suggesting old healed tuberculosis. J Korean Med Sci 29(3):386–391. doi:10.3346/jkms.2014.29.3.386
101. 18F-FDG-PET-CT scanning in patients with granulomatous disease. Nucl Med Commun 36(5):430–437. doi:10.1097/MNM.0000000000000274
102. 18F-FDG PET/CT and MRI of the spine in the diagnosis of haematogenous spondylodiscitis. Eur J Nucl Med Mol Imaging 42(2):246–271. doi:10.1007/s00259-014-2898-0
103. Castaigne C, Tondeur M, de Wit S, Hildebrand M, Clumeck N, Dusart M (2009) Clinical value of FDG-PET/CT for the diagnosis of human immunodeficiency virus-associated fever of unknown origin: a retrospective study. Nucl Med Commun 30(1):41–47
104. Liu Q, Peng ZM, Liu QW, Yao SZ, Zhang L, Meng L, Chen JH (2006) The role of 11C-choline positron emission tomography–computed tomography and videomediastinoscopy in the evaluation of diseases of middle mediastinum. Chin Med J 119(8):634–639
105. Hara T, Inagaki K, Kosaka N, Morita T (2000) Sensitive detection of mediastinal lymph node metastasis of lung cancer with 11C-choline PET. J Nuc Med 41(9):1507–1513
106. 18F-ethylcholine. Open Nucl Med J 6:17–21. doi:10.2174/1876388X01406010017
107. 18F-FDG. J Nucl Med 49(2):186–194. doi:10.2967/jnumed.107.044966
108. 18F-FDG/F-FLT PET/CT benefit the diagnosis and management of patients with pulmonary lesions? Eur J Nucl Med Mol Imaging 38(2):285–292. doi:10.1007/s00259-010-1625-8
109. 68Ga-citrate PET/CT in the characterization of indeterminate lung lesions. Ann Nucl Med 28(6):523–530. doi:10.1007/s12149-014-0842-9
110. Vorster M, Maes A, Van de Wiele C, Sathekge MM. 68 Ga-citrate PET/CT in tuberculosis: A pilot study. Q J Nucl Med Mol Imaging (Epub ahead of print)
111. Ordenez AA, DeMarco VP, Klunk MH, Pokkali S, Jain SK (2015) Imaging chronic tuberculosis lesions using sodium [18F]Fluoride positron emmission tomography in mice. Mol Imaging Biol 17(5):609–614. doi:10.1007/s11307-015-0836-6
112. Liu L, Xu Y, Shea C, Fowler JS, Hooker JM, Tonge PJ (2010) Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, rifampicin and pyrazinamide in baboons. J Med Chem 53(7):2882–2891. doi:10.1021/jm901858n
113. Adams KN, Takaki K, Connolly LE, Wiedenhoft H, Winglee K, Humbert O et al (2011) Drug tolerance in replicating mediated by macrophage-induced efflux mechanism. Cell 145(1):39–53. doi:10.1016/j.cell.2011.02.022
114. van der Werf TS, Dade GK, van der Mark TW (1990) Patient compliance with tuberculosis treatment in Ghana: factors influencing adherence to therapy in a rural service programme. Tubercle 71(4):247–252
115. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR et al (2014) Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 371(17):1577–1587. doi:10.1056/NEJMoa1407426
116. Guidelines for the treatment of tuberculosis (4thed) 2010: Geneva World Health Organization. www.who.int/tb/publications/2010/9789241547833/en. Assessed on 23 Nov 2015
117. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM (2009) Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS ONE 4(9):e6914. doi:10.1371/journal.pone.0006914
118. van Altena R, de Vries G, Haar CH, de Lange WC, Magis-Escurra C, van den Hof S, van Soolingen D, Boeree MJ, van der Werf TS (2015) Highly successful treatment outcome of multidrug-resistant tuberculosis in the Netherlands, 2000–2009. Int J Tuberc Lung Dis 19(4):406–412. doi:10.5588/ijtld.14.0838
119. Sia I, Wieland M (2011) Current concept in the management of tuberculosis. Mayo Clin Proc 86(4):348–361. doi:10.4065/mcp.2010.0820
120. Guidelines on the management of latent tuberculosis infection 2015: Geneva World Health Organization. www.who.int/tb/publications/ltbi_document_page/en/. Assessed on the 23 Nov 2015
121. Alsaad N, Wilffert B, van Altena R, de Lange WC, van der Werf TS, Kosterink JG, Alffenaar JW (2014) Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis. Eur Respir J 43(3):884–897. doi:10.1183/09031936.00113713